Clearbridge Health Ltd. · SGX:1H3
Clearbridge Health — Investor Presentation (March 2018)
34 slides from Clearbridge Health's investor presentation, March 2018
Slide 1: Redefining Asia’s Medical Insights and Personalised Patientcare
Redefining Asia’s Medical Insights and Personalised Patientcare Corporate Presentation March 2018
Slide 2: Important notice
Important notice Clearbridge Health Limited (the “Company”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) on 18 December 2017. This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, United Overseas
Slide 3: Important notice
Important notice This presentation may contain forward-looking statements with respect to the Company’s financial position, business strategies, plans and prospects. These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the Company’s actual r
Slide 4: Contents
Contents 1. About our 2. Competitive 3. Corporate strengths & business developments growth plans 4. Financial 5. Prospects 6. Summary highlights 4
Slide 5: About Our Business
About Our Business
Slide 6: Patient care is our emphasis
Patient care is our emphasis MISSION To improve patient care by making precision medicine solutions readily available to clinicians and patients in Asia VISION Empower clinicians and healthcare professionals to make more accurate and reliable diagnoses , provide insights to disease management and ta
Slide 7: Precision medicine…
Precision medicine… Tailors medical treatment and prevention regimes to the individual profile of patients Precision medicine vs standard therapy PATIENT POPULATION Precision medicine has proven positive clinical outcomes •Increased survival for several diseases MEDICAL including blood cancers TECHN
Slide 8: Business overview
Business overview Clearbridge Health is a healthcare company with a focus on the delivery of precision medicine in Asia Provide laboratory testing services Strategic equity Own and operate participation in medical clinics / precision medical centres technology companies 8
Slide 9: Business model
Business model Enables delivery of precision medicine in Asia Economic Rights MedTech Areas MEDICAL CLINICS/CENTRES AND SERVICES •Subsidiaries – •Genomics Lifestyle CBBP •Metabolomics and Market and distribute our •Associates – •Liquid Biopsies Wellness laboratory testing services CBB, SIAMH •Others
Slide 10: Corporate structure
Corporate structure CLEARBRIDGE HEALTH LIMITED 100% 100% 100% 100% 100% Clearbridge Clearbridge SAM Laboratory Clearbridge BSA Clearbridge Lifestyle Asia Pte. Medical Group Pte. Ltd. (SAM Pte. Ltd. (CBBSA) Assays Pte. Ltd. Ltd. Pte. Ltd. (CBMG) Labs) 2.22%(1) 39.70%(2) 26.85%(3) 20.98%(3) 100% 100%
Slide 11: Laboratory testing services
Laboratory testing services Comprehensive suite of services to meet customers’ needs Clinical •• Health screening and management for general patient care Range of oncology diagnostics tests covering cancer diagnosis, Diagnostics biomarker diagnostics and treatment monitoring and prognosis • In-house
Slide 12: Own and operate medical clinics/centres
Own and operate medical clinics/centres Providing market access for laboratory testing services • Currently owns and operates three medical clinics / centres in • Singapore (August 2017) • Hong Kong (July 2017) • the Philippines (January 2018) • Distinguishing factor - Data-driven approach 12
Slide 13: Medical technologies owned and/or offered by us and our associated companies
Medical technologies owned and/or offered by us and our associated companies Medical • Subsidiary and associated companies in medical technology segment, which complements our Technology business • An associated company which owns and operates a • A subsidiary developing an • An associated company m
Slide 14: Collaborations with third parties
Collaborations with third parties Providing technology access and product & service enhancements Tapping on a network of technology and clinical partners to: Enhance product and service offerings Gain access to cutting edge R&D activities Research and develop new products and services …and more… 14
Slide 15: Competitive Strengths & Growth Plans
Competitive Strengths & Growth Plans
Slide 16: Complementary business segments
Complementary business segments One of the first companies in Asia to cater to different segments of the medical industry Laboratory testing services • Access to products / services • Direct access to patients • Strengthen market awareness through • Additional marketing channels for relationships wi
Slide 17: Technology agnostic, holistic & patient-centric
Technology agnostic, holistic & patient-centric Positions us well to deliver precision medicine across Asia Technology agnostic approach allows us to take advantage of the best-in-class technologies and workflows; and provide a wide range of products and/or services To provide better purpose-suited
Slide 18: An experienced management team
An experienced management team To lead and execute our business strategy • Previously CEO of Cordlife Group Limited, a Jeremy Yee SGX listed healthcare company Executive Director • Previously CFO of Cordlife Limited(1) an ASX and CEO listed healthcare company • M.Comm (University of Sydney), MBA (Ch
Slide 19: Growth plans
Growth plans Expand our medical clinics Expand laboratory testing Enhance internal / centres regionally services capabilities; achieve •Intend to leverage early greater efficiencies & entrant advantage to returns •Intend to collaborate with local partners in Indonesia, raise brand awareness •Intend
Slide 20: Corporate Developments
Corporate Developments
Slide 21: IPO Promises Delivered
IPO Promises Delivered Clearbridge executed its growth plans immediately after its Dec 2017 IPO with 1 business collaboration and 3 acquisitions in just 2 months √ Acquisition √ Proposed √ Proposed √ Business in the acquisition in acquisition in Collaboration Philippines Singapore Indonesia Jan 2018
Slide 22: Expansion of Product Offering
Expansion of Product Offering Through Business Collaboration with MILS International (“MILS”) • Jan 2018: Appointed exclusive distributor of MILS’s full range of diagnostic tests in 11 countries – Singapore, India, Indonesia, Malaysia, the Philippines, Korea, Taiwan, Thailand, Vietnam, Australia and
Slide 23: Regional Expansion of Medical Clinics/Centres
Regional Expansion of Medical Clinics/Centres Through Acquisitions The Philippines Singapore Indonesia • Jan 2018: Completed • Feb 2018: Entered into • Feb 2018: Entered into acquisition of a 65% conditional sale and SPA for proposed equity interest in purchase agreement acquisition of controlling P
Slide 24: Financial Highlights
Financial Highlights
Slide 25: Key highlights
Key highlights Revenue and profit Financial years ended 31 December For the Period Under Review, revenue was due mainly to the acquisitions of CMBG and SAM Lab in S$’000 FY16 FY17 May 2017 and Aug 2017 respectively: •Revenue contribution from CMBG was mainly derived from the medical centre in Hong K
Slide 26: Key financial highlights
Key financial highlights Balance sheet As at As at • Asset light with low debt S$’000 31 Dec 2016 31 Dec 2017 Cash and cash • Purchased the Mapex 4,308 27,740 equivalents Property, a freehold office unit for our own use for S$2.05 Total assets 46,671 68,793 million on 13 Nov 2017. • Expect to see co
Slide 27: Prospects
4 E, = 1 o D&S _— Prospects rH | | J
Slide 28: Singapore
Singapore Factors supporting demand for healthcare A medical tourism hub in Southeast Asia Rising affluence; • Pool of middle-to-affluent- Better education class population in Population growth; Southeast Asia able to Longer life afford private healthcare to • Median household income reach 382 milli
Slide 29: Regional opportunities for growth
Regional opportunities for growth • Growing demand for • Rising revenues of global private private healthcare health insurance industry: insurance is partially a ‐ 2016: €1.3 trillion result of increasing ‐ By 2025: €2.6 trillion(6) interest in healthcare services • Intensifying economic • Countries
Slide 30: Pace of technological innovation
Pace of technological innovation • Reduction in cost coupled with improved technologies for biomedical analysis and management of large data sets is These developments will likely to accelerate the application increase the awareness of of precision medicine the efficacy of precision medicine and hig
Slide 31: Summary
Summary 31
Slide 32: In summary
In summary We are a healthcare 1. Our belief in Patient- 2. Precision medicine company focused on Centric Care shapes how tailors medical treatment precision medicine we conduct our businesses and prevention regimes to services and operations an individual’s profile 3. Technology agnostic 4. Complem
Slide 33: Thank you
Thank you
Slide 34: Appendix
Appendix References 1. Information obtained from a report issued in January 2013 entitled “A Sustainable Population for a Dynamic Singapore, Population White Paper" published on the website of the Strategy Group, Prime Minister’s Office. (https://www.strategygroup.gov.sg/docs/default- source/Populat
Clearbridge Health — Investor Presentation (March 2018) on 6ix